Do analysts prefer KARD or ELYM?

Kardigan currently has a consensus price target of $38.80, indicating a potential upside of 199.15%. Given Kardigan's stronger consensus rating and higher possible upside, equities research analysts plainly believe Kardigan is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kardigan 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, KARD or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Kardigan, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kardigan N/A N/A -$191.94M -$2.88 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is KARD or ELYM more profitable?

Kardigan's return on equity of 0.00% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kardigan N/A N/A N/A Eliem Therapeutics N/A -47.03% -45.97%

Do analysts prefer ELYM or REPL?

Replimune Group has a consensus target price of $12.00, suggesting a potential downside of 0.91%. Given Replimune Group's stronger consensus rating and higher probable upside, analysts plainly believe Replimune Group is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Replimune Group 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has better earnings & valuation, ELYM or REPL?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A Replimune Group N/A N/A -$313.94M -$3.15 N/A

Is ELYM or REPL more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Replimune Group N/A -159.32% -90.84%

Do analysts prefer ORIC or ELYM?

Oric Pharmaceuticals presently has a consensus target price of $20.67, indicating a potential upside of 82.73%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Oric Pharmaceuticals is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oric Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.81 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, ORIC or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is ORIC or ELYM more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Eliem Therapeutics N/A -47.03% -45.97%

Do analysts recommend TYRA or ELYM?

Tyra Biosciences currently has a consensus target price of $47.20, suggesting a potential upside of 154.31%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Tyra Biosciences is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tyra Biosciences 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.93 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, TYRA or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tyra Biosciences N/A N/A -$119.95M -$2.40 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is TYRA or ELYM more profitable?

Tyra Biosciences' return on equity of -46.39% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tyra Biosciences N/A -46.39% -43.07% Eliem Therapeutics N/A -47.03% -45.97%

Which has preferable valuation & earnings, ELYM or DMRA?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A

Is ELYM or DMRA more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86%

Eliem Therapeutics (ELYM) Competitors

$10.31 -0.52 (-4.80%)

As of 10/13/2026

Compare

ELYM vs. KARD, REPL, ORIC, TYRA, and DMRA

Should you buy Eliem Therapeutics stock or one of its competitors? Eliem Therapeutics's main competitors and comparable companies include Kardigan (KARD), Replimune Group (REPL), Oric Pharmaceuticals (ORIC), Tyra Biosciences (TYRA), and Damora Therapeutics, Inc. Common Stock (DMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eliem Therapeutics compare to Kardigan?

Kardigan (NASDAQ:KARD) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

In the previous week, Kardigan had 2 more articles in the media than Eliem Therapeutics. MarketBeat recorded 2 mentions for Kardigan and 0 mentions for Eliem Therapeutics. Kardigan's average media sentiment score of 0.41 beat Eliem Therapeutics' score of 0.00 indicating that Kardigan is being referred to more favorably in the media.

Company	Overall Sentiment
Kardigan	Neutral
Eliem Therapeutics	Neutral

Kardigan currently has a consensus price target of $38.80, indicating a potential upside of 199.15%. Given Kardigan's stronger consensus rating and higher possible upside, equities research analysts plainly believe Kardigan is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kardigan	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Kardigan, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kardigan	N/A	N/A	-$191.94M	-$2.88	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Kardigan's return on equity of 0.00% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kardigan	N/A	N/A	N/A
Eliem Therapeutics	N/A	-47.03%	-45.97%

69.8% of Eliem Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Kardigan beats Eliem Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Eliem Therapeutics compare to Replimune Group?

Eliem Therapeutics (NASDAQ:ELYM) and Replimune Group (NASDAQ:REPL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

In the previous week, Replimune Group had 5 more articles in the media than Eliem Therapeutics. MarketBeat recorded 5 mentions for Replimune Group and 0 mentions for Eliem Therapeutics. Replimune Group's average media sentiment score of 0.70 beat Eliem Therapeutics' score of 0.00 indicating that Replimune Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Replimune Group	Positive

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

Eliem Therapeutics' return on equity of -47.03% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Replimune Group	N/A	-159.32%	-90.84%

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Replimune Group has a consensus target price of $12.00, suggesting a potential downside of 0.91%. Given Replimune Group's stronger consensus rating and higher probable upside, analysts plainly believe Replimune Group is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Replimune Group beats Eliem Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Eliem Therapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Oric Pharmaceuticals' return on equity of -35.35% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Oric Pharmaceuticals has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market.

Oric Pharmaceuticals presently has a consensus target price of $20.67, indicating a potential upside of 82.73%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Oric Pharmaceuticals is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Eliem Therapeutics. MarketBeat recorded 2 mentions for Oric Pharmaceuticals and 0 mentions for Eliem Therapeutics. Oric Pharmaceuticals' average media sentiment score of 0.48 beat Eliem Therapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Oric Pharmaceuticals	Neutral
Eliem Therapeutics	Neutral

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Oric Pharmaceuticals beats Eliem Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Eliem Therapeutics compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

84.1% of Tyra Biosciences shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

In the previous week, Tyra Biosciences had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for Tyra Biosciences and 0 mentions for Eliem Therapeutics. Tyra Biosciences' average media sentiment score of 0.61 beat Eliem Therapeutics' score of 0.00 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tyra Biosciences	Positive
Eliem Therapeutics	Neutral

Tyra Biosciences has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

Tyra Biosciences currently has a consensus target price of $47.20, suggesting a potential upside of 154.31%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Tyra Biosciences is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Tyra Biosciences' return on equity of -46.39% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Summary

Tyra Biosciences beats Eliem Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Eliem Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Eliem Therapeutics (NASDAQ:ELYM) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eliem Therapeutics' return on equity of -47.03% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%

Damora Therapeutics, Inc. Common Stock has a consensus target price of $46.50, suggesting a potential upside of 150.54%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A

In the previous week, Damora Therapeutics, Inc. Common Stock had 4 more articles in the media than Eliem Therapeutics. MarketBeat recorded 4 mentions for Damora Therapeutics, Inc. Common Stock and 0 mentions for Eliem Therapeutics. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.60 beat Eliem Therapeutics' score of 0.00 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Damora Therapeutics, Inc. Common Stock	Positive

Summary

Damora Therapeutics, Inc. Common Stock beats Eliem Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Eliem Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELYM vs. The Competition

Export

Metric	Eliem Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$306.74M	$3.88B	$7.25B	$13.04B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-19.45	13.03	275.44	25.51
Price / Sales	N/A	1,148.01	562.05	79.58
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	2.64	16.75	10.64	6.00
Net Income	-$35.12M	-$22.65M	$3.49B	$380.50M
7 Day Performance	-3.46%	-4.89%	-3.21%	-3.35%
1 Month Performance	-27.65%	-12.84%	-7.65%	-6.23%
1 Year Performance	415.50%	7.43%	2.92%	-3.96%

Eliem Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELYM Eliem Therapeutics	N/A	$10.31 -4.8%	N/A	+501.7%	$306.74M	N/A	N/A	9
KARD Kardigan	3.1728 of 5 stars	$13.83 +2.5%	$42.25 +205.5%	N/A	$1.26B	N/A	N/A	241	News Coverage Analyst Upgrade Short Interest Increase
REPL Replimune Group	1.0958 of 5 stars	$13.20 -0.4%	$12.00 -9.1%	+165.6%	$1.24B	N/A	N/A	465
ORIC Oric Pharmaceuticals	3.0869 of 5 stars	$12.01 +0.3%	$20.67 +72.1%	-18.7%	$1.24B	N/A	N/A	111	Analyst Forecast
TYRA Tyra Biosciences	3.1884 of 5 stars	$20.39 +0.7%	$47.20 +131.5%	+29.2%	$1.21B	N/A	N/A	87

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELYM) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eliem Therapeutics (ELYM) Competitors

ELYM vs. KARD, REPL, ORIC, TYRA, and DMRA

How does Eliem Therapeutics compare to Kardigan?

Summary

How does Eliem Therapeutics compare to Replimune Group?

Summary

How does Eliem Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Eliem Therapeutics compare to Tyra Biosciences?

Summary

How does Eliem Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eliem Therapeutics (ELYM) Competitors

ELYM vs. KARD, REPL, ORIC, TYRA, and DMRA

How does Eliem Therapeutics compare to Kardigan?

Does the media refer more to KARD or ELYM?

Do analysts prefer KARD or ELYM?

Which has higher earnings and valuation, KARD or ELYM?

Is KARD or ELYM more profitable?

Do insiders & institutionals believe in KARD or ELYM?

Summary

How does Eliem Therapeutics compare to Replimune Group?

Does the media refer more to ELYM or REPL?

Which has better earnings & valuation, ELYM or REPL?

Is ELYM or REPL more profitable?

Do institutionals and insiders have more ownership in ELYM or REPL?

Which has more risk & volatility, ELYM or REPL?

Do analysts prefer ELYM or REPL?

Summary

How does Eliem Therapeutics compare to Oric Pharmaceuticals?

Is ORIC or ELYM more profitable?

Which has preferable valuation and earnings, ORIC or ELYM?

Which has more risk & volatility, ORIC or ELYM?

Do analysts prefer ORIC or ELYM?

Does the media prefer ORIC or ELYM?

Do insiders and institutionals believe in ORIC or ELYM?

Summary

How does Eliem Therapeutics compare to Tyra Biosciences?

Do institutionals & insiders have more ownership in TYRA or ELYM?

Which has preferable earnings & valuation, TYRA or ELYM?

Does the media prefer TYRA or ELYM?

Which has more volatility and risk, TYRA or ELYM?

Do analysts recommend TYRA or ELYM?

Is TYRA or ELYM more profitable?

Summary

How does Eliem Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Do institutionals & insiders hold more shares of ELYM or DMRA?

Is ELYM or DMRA more profitable?

Do analysts rate ELYM or DMRA?

Which has more volatility & risk, ELYM or DMRA?

Which has preferable valuation & earnings, ELYM or DMRA?

Does the media favor ELYM or DMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools